Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Acosta

Showing results (151-160 of 338) with videos related to

Pageof 34
Sort By:
The Lancet. Respiratory Medicine|May 18, 2016
Pilot evaluation of ivacaftor for chronic bronchitisGeorge M Solomon, Heather Hathorne, Bo Liu, et al.
The Journal of Antimicrobial Chemotherapy|April 15, 2014
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypesDavid W Haas, Awewura Kwara, Danielle M Richardson, et al.
Salud Publica De Mexico|February 24, 2001
Comparison among three methods for mycobacteria identificationM Mondragón-Barreto, C A Vázquez-Chacón, C Barrón-Rivero, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2011
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patientsJennifer R King, Ram Yogev, Patrick Jean-Philippe, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2012
Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experienceMina Nikanjam, Desiré Kabamba, Tim R Cressey, et al.
The Journal of Infectious Diseases|April 19, 2008
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell countsHeather J Ribaudo, Daniel R Kuritzkes, Christina M Lalama, et al.
Physical Review Letters|October 15, 2008
Positioning of strained islands by interaction with surface nanogroovesG Katsaros, J Tersoff, M Stoffel, et al.
Clinical Pharmacokinetics|December 7, 2013
Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patientsKun Wang, David Z D'Argenio, Edward P Acosta, et al.
Pediatric Pulmonology|August 4, 2022
Plasma and cellular ivacaftor concentrations in patients with cystic fibrosisJennifer S Guimbellot, Kevin J Ryan, Justin D Anderson, et al.
AIDS (London, England)|March 3, 2006
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitnessDavid R Bangsberg, Edward P Acosta, Reena Gupta, et al.
Pageof 34

Showing results (151-160 of 338) with videos related to

Sort By:
Pageof 34
The Lancet. Respiratory Medicine|May 18, 2016
Pilot evaluation of ivacaftor for chronic bronchitisGeorge M Solomon, Heather Hathorne, Bo Liu, et al.
The Journal of Antimicrobial Chemotherapy|April 15, 2014
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypesDavid W Haas, Awewura Kwara, Danielle M Richardson, et al.
Salud Publica De Mexico|February 24, 2001
Comparison among three methods for mycobacteria identificationM Mondragón-Barreto, C A Vázquez-Chacón, C Barrón-Rivero, et al.
Antimicrobial Agents and Chemotherapy|June 15, 2011
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patientsJennifer R King, Ram Yogev, Patrick Jean-Philippe, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2012
Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experienceMina Nikanjam, Desiré Kabamba, Tim R Cressey, et al.
The Journal of Infectious Diseases|April 19, 2008
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell countsHeather J Ribaudo, Daniel R Kuritzkes, Christina M Lalama, et al.
Physical Review Letters|October 15, 2008
Positioning of strained islands by interaction with surface nanogroovesG Katsaros, J Tersoff, M Stoffel, et al.
Clinical Pharmacokinetics|December 7, 2013
Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patientsKun Wang, David Z D'Argenio, Edward P Acosta, et al.
Pediatric Pulmonology|August 4, 2022
Plasma and cellular ivacaftor concentrations in patients with cystic fibrosisJennifer S Guimbellot, Kevin J Ryan, Justin D Anderson, et al.
AIDS (London, England)|March 3, 2006
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitnessDavid R Bangsberg, Edward P Acosta, Reena Gupta, et al.
Pageof 34